Search

Most complex diseases, including cancer and non-malignant diseases like asthma, have distinct molecular subtypes that require distinct clinical approaches. However, existing computational patient stratification methods have been benchmarked almost exclusively on cancer omics data and only perform well when mutually exclusive subtypes can be characterized by many biomarkers. Here, we contribute with a massive evaluation attempt, quantitatively exploring the power of 22 unsupervised patient stratification methods using both, simulated and real transcriptome data. From this experience, we developed UnPaSt (https://apps.cosy.bio/unpast/) optimizing unsupervised patient stratification, working even with only a limited number of subtype-predictive biomarkers. We evaluated all 23 methods on real-world breast cancer and asthma transcriptomics data. Although many methods reliably detected major breast cancer subtypes, only few identified Th2-high asthma, and UnPaSt significantly outperformed its closest competitors in both test datasets. Essentially, we showed that UnPaSt can detect many biologically insightful and reproducible patterns in omic datasets., Comment: The first two authors listed are joint first authors. The last two authors listed are joint last authors

Quantitative mass spectrometry has revolutionized proteomics by enabling simultaneous quantification of thousands of proteins. Pooling patient-derived data from multiple institutions enhances statistical power but raises significant privacy concerns. Here we introduce FedProt, the first privacy-preserving tool for collaborative differential protein abundance analysis of distributed data, which utilizes federated learning and additive secret sharing. In the absence of a multicenter patient-derived dataset for evaluation, we created two, one at five centers from LFQ E.coli experiments and one at three centers from TMT human serum. Evaluations using these datasets confirm that FedProt achieves accuracy equivalent to DEqMS applied to pooled data, with completely negligible absolute differences no greater than $\text{$4 \times 10^{-12}$}$. In contrast, -log10(p-values) computed by the most accurate meta-analysis methods diverged from the centralized analysis results by up to 25-27. FedProt is available as a web tool with detailed documentation as a FeatureCloud App., Comment: 52 pages, 16 figures, 12 tables. Last two authors listed are joint last authors

In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research., Comment: 45 pages, 6 figures, 7 tables

Current-generation Large Language Models (LLMs) have stirred enormous interest in recent months, yielding great potential for accessibility and automation, while simultaneously posing significant challenges and risk of misuse. To facilitate interfacing with LLMs in the biomedical space, while at the same time safeguarding their functionalities through sensible constraints, we propose a dedicated, open-source framework: BioChatter. Based on open-source software packages, we synergise the many functionalities that are currently developing around LLMs, such as knowledge integration / retrieval-augmented generation, model chaining, and benchmarking, resulting in an easy-to-use and inclusive framework for application in many use cases of biomedicine. We focus on robust and user-friendly implementation, including ways to deploy privacy-preserving local open-source LLMs. We demonstrate use cases via two multi-purpose web apps (https://chat.biocypher.org), and provide documentation, support, and an open community., Comment: 31 pages, 3 figures

Standardising the representation of biomedical knowledge among all researchers is an insurmountable task, hindering the effectiveness of many computational methods. To facilitate harmonisation and interoperability despite this fundamental challenge, we propose to standardise the framework of knowledge graph creation instead. We implement this standardisation in BioCypher, a FAIR (findable, accessible, interoperable, reusable) framework to transparently build biomedical knowledge graphs while preserving provenances of the source data. Mapping the knowledge onto biomedical ontologies helps to balance the needs for harmonisation, human and machine readability, and ease of use and accessibility to non-specialist researchers. We demonstrate the usefulness of this framework on a variety of use cases, from maintenance of task-specific knowledge stores, to interoperability between biomedical domains, to on-demand building of task-specific knowledge graphs for federated learning. BioCypher (https://biocypher.org) frees up valuable developer time; we encourage further development and usage by the community., Comment: 34 pages, 6 figures; submitted to Nature Biotechnology

Federated learning (FL) enables multiple clients to jointly train a global model under the coordination of a central server. Although FL is a privacy-aware paradigm, where raw data sharing is not required, recent studies have shown that FL might leak the private data of a client through the model parameters shared with the server or the other clients. In this paper, we present the HyFed framework, which enhances the privacy of FL while preserving the utility of the global model. HyFed provides developers with a generic API to develop federated, privacy-preserving algorithms. HyFed supports both simulation and federated operation modes and its source code is publicly available at https://github.com/tum-aimed/hyfed.

Machine Learning (ML) and Artificial Intelligence (AI) have shown promising results in many areas and are driven by the increasing amount of available data. However, this data is often distributed across different institutions and cannot be shared due to privacy concerns. Privacy-preserving methods, such as Federated Learning (FL), allow for training ML models without sharing sensitive data, but their implementation is time-consuming and requires advanced programming skills. Here, we present the FeatureCloud AI Store for FL as an all-in-one platform for biomedical research and other applications. It removes large parts of this complexity for developers and end-users by providing an extensible AI Store with a collection of ready-to-use apps. We show that the federated apps produce similar results to centralized ML, scale well for a typical number of collaborators and can be combined with Secure Multiparty Computation (SMPC), thereby making FL algorithms safely and easily applicable in biomedical and clinical environments.

COVID-19 is an infection caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), which has caused a global outbreak. Current research efforts are focused on the understanding of the molecular mechanisms involved in SARS-CoV-2 infection in order to propose drug-based therapeutic options. Transcriptional changes due to epigenetic regulation are key host cell responses to viral infection and have been studied in SARS-CoV and MERS-CoV; however, such changes are not fully described for SARS-CoV-2. In this study, we analyzed multiple transcriptomes obtained from cell lines infected with MERS-CoV, SARS-CoV and SARS-CoV-2, and from COVID-19 patient-derived samples. Using integrative analyses of gene co-expression networks and de-novo pathway enrichment, we characterize different gene modules and protein pathways enriched with Transcription Factors or Epifactors relevant for SARS-CoV-2 infection. We identified EP300, MOV10, RELA and TRIM25 as top candidates, and more than 60 additional proteins involved in the epigenetic response during viral infection that have therapeutic potential. Our results show that targeting the epigenetic machinery could be a feasible alternative to treat COVID-19., Comment: 33 pages, 2 tables, 5 figures, 4 supplementary figures

Federated learning has faced performance and network communication challenges, especially in the environments where the data is not independent and identically distributed (IID) across the clients. To address the former challenge, we introduce the federated-centralized concordance property and show that the federated single-mini-batch training approach can achieve comparable performance as the corresponding centralized training in the Non-IID environments. To deal with the latter, we present the federated multi-mini-batch approach and illustrate that it can establish a trade-off between the performance and communication efficiency and outperforms federated averaging in the Non-IID settings.

Aggregating transcriptomics data across hospitals can increase sensitivity and robustness of differential expression analyses, yielding deeper clinical insights. As data exchange is often restricted by privacy legislation, meta-analyses are frequently employed to pool local results. However, if class labels are inhomogeneously distributed between cohorts, their accuracy may drop. Flimma (https://exbio.wzw.tum.de/flimma/) addresses this issue by implementing the state-of-the-art workflow limma voom in a privacy-preserving manner, i.e. patient data never leaves its source site. Flimma results are identical to those generated by limma voom on combined datasets even in imbalanced scenarios where meta-analysis approaches fail., Comment: 27 pages, 7 figures

Artificial intelligence (AI) has been successfully applied in numerous scientific domains. In biomedicine, AI has already shown tremendous potential, e.g. in the interpretation of next-generation sequencing data and in the design of clinical decision support systems. However, training an AI model on sensitive data raises concerns about the privacy of individual participants. For example, summary statistics of a genome-wide association study can be used to determine the presence or absence of an individual in a given dataset. This considerable privacy risk has led to restrictions in accessing genomic and other biomedical data, which is detrimental for collaborative research and impedes scientific progress. Hence, there has been a substantial effort to develop AI methods that can learn from sensitive data while protecting individuals' privacy. This paper provides a structured overview of recent advances in privacy-preserving AI techniques in biomedicine. It places the most important state-of-the-art approaches within a unified taxonomy and discusses their strengths, limitations, and open problems. As the most promising direction, we suggest combining federated machine learning as a more scalable approach with other additional privacy preserving techniques. This would allow to merge the advantages to provide privacy guarantees in a distributed way for biomedical applications. Nonetheless, more research is necessary as hybrid approaches pose new challenges such as additional network or computation overhead., Comment: 17 pages, 3 figures, 3 tables. Methods of Information in Medicine (2022)

Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. It was first identified in Wuhan, China, and has since spread causing a global pandemic. Various studies have been performed to understand the molecular mechanisms of viral infection for predicting drug repurposing candidates. However, such information is spread across many publications and it is very time-consuming to access, integrate, explore, and exploit. We developed CoVex, the first interactive online platform for SARS-CoV-2 and SARS-CoV-1 host interactome exploration and drug (target) identification. CoVex integrates 1) experimentally validated virus-human protein interactions, 2) human protein-protein interactions and 3) drug-target interactions. The web interface allows user-friendly visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drugs. Thus, CoVex is an important resource, not only to understand the molecular mechanisms involved in SARS-CoV-2 and SARS-CoV-1 pathogenicity, but also in clinical research for the identification and prioritization of candidate therapeutics. We apply CoVex to investigate recent hypotheses on a systems biology level and to systematically explore the molecular mechanisms driving the virus life cycle. Furthermore, we extract and discuss drug repurposing candidates involved in these mechanisms. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms integrating virus-host-drug interactions. It is available at https://exbio.wzw.tum.de/covex/., Comment: 15 pages, 4 figures

Identifying groups of similar objects using clustering approaches is one of the most frequently employed first steps in exploratory biomedical data analysis. Many clustering methods have been developed that pursue different strategies to identify the optimal clustering for a data set. We previously published TiCoNE, an interactive clustering approach coupled with de-novo network enrichment of identified clusters. However, in this first version time-series and network analysis remained two separate steps in that only time-series data was clustered, and identified clusters mapped to and enriched within a network in a second separate step. In this work, we present TiCoNE 2: An extension that can now seamlessly incorporate multiple data types within its composite clustering model. Systematic evaluation on 50 random data sets, as well as on 2,400 data sets containing enriched cluster structure and varying levels of noise, shows that our approach is able to successfully recover cluster patterns embedded in random data and that it is more robust towards noise than non-composite models using only one data type, when applied to two data types simultaneously. Herein, each data set was clustered using five different similarity functions into k=10/30 clusters, resulting to ~5,000 clusterings in total. We evaluated the quality of each derived clustering with the Jaccard index and an internal validity score. We used TiCoNE to calculate empirical p-values for all generated clusters with different permutation functions, resulting in ~80,000 cluster p-values. We show, that derived p-values can be used to reliably distinguish between foreground and background clusters. TiCoNE 2 allows researchers to seamlessly analyze time-series data together with biological interaction networks in an intuitive way and thereby provides more robust results than single data type cluster analyses.

Advances in OMICS technologies emerged both massive expression data sets and huge networks modelling the molecular interplay of genes, RNAs, proteins and metabolites. Network enrichment methods combine these two data types to extract subnetwork responses from case/control setups. However, no methods exist to integrate time series data with networks, thus preventing the identification of time-dependent systems biology responses. We close this gap with Time Course Network Enrichment (TiCoNE). It combines a new kind of human-augmented clustering with a novel approach to network enrichment. It finds temporal expression prototypes that are mapped to a network and investigated for enriched prototype pairs interacting more often than expected by chance. Such patterns of temporal subnetwork co-enrichment can be compared between different conditions. With TiCoNE, we identified the first distinguishing temporal systems biology profiles in time series gene expression data of human lung cells after infection with Influenza and Rhino virus. TiCoNE is available online (https://ticone.compbio.sdu.dk) and as Cytoscape app in the Cytoscape App Store (http://apps.cytoscape.org/).